What does CORIPHAR do?

CORIPHAR is a pharmacy in Tienen. Private Limited, started on 4 April 1989, 1 establishment.

What is the address of CORIPHAR?

The registered office of CORIPHAR is located at Getestraat 81, 3300 Tienen.

Is CORIPHAR still active?

Yes. According to the CBE (30 October 2026) CORIPHAR is active, legal situation “Normale toestand”, started on 4 April 1989.

Is CORIPHAR registered on Peppol?

Yes, CORIPHAR is registered on the Peppol network with ID 0208:0437150690.

What is the enterprise number of CORIPHAR?

The enterprise number of CORIPHAR is BE0437150690.

When was CORIPHAR founded?

CORIPHAR was founded on 4 April 1989.

Who are the directors of CORIPHAR?

According to the 2025 annual accounts, the directors of CORIPHAR are: Apotheek Tramstatie.

Is CORIPHAR a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 4 April 1989; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did CORIPHAR make in 2025?

CORIPHAR posted a profit after taxes of € 25,225 in financial year 2025.

What is the revenue of CORIPHAR?

As a small company, CORIPHAR is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 55,990.

How many employees does CORIPHAR have?

According to the 2025 annual accounts, CORIPHAR has 0.3 full-time equivalents (FTE).

CORIPHAR (Private Limited) - Tienen - BE0437150690

Dossier CORIPHAR, printed on 30 October 2026 from databakkes.be/en/0437150690/coriphar. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

CORIPHAR from Tienen, company number BE0437150690, closed financial year 2025 with a result of € 25,225 after tax. For that financial year CORIPHAR recorded a gross margin of € 55,990 and equity of € 146,896. Compared with financial year 2024, the result moved from € 87,380 to € 25,225. The company is profitable. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on August 28, 2026.

What it is worth Growing

€ 146,896

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 25,225

▼ 71% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 62,294

▼ 23% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 25,200 paid out

100 % of the profit went to the shareholders, mostly to APOTHEEK TRAMSTATIE (100 % of the shares). That is where the money ends up.

People and assets in 2025

Full-time equivalents

0.3

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 15,479

▲ 7% vs 2024

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 188

▼ 90% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 4 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 86,624

▼ 19% vs 2024

€ 20,004 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.

Owed to suppliers

€ 160,791

▲ 6% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 5,731

▼ 30% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 133,794 Gross margin 2022: € 133,794 First fiscal year in the series	€ 50,150 Gross margin 2023: € 50,150 ▼ 63% vs 2022 (€ 133,794) Unfavourable step	€ 79,297 Gross margin 2024: € 79,297 ▲ 58% vs 2023 (€ 50,150) Favourable step	€ 55,990 Gross margin 2025: € 55,990 ▼ 29% vs 2024 (€ 79,297) Unfavourable step	▼ 29%
Profit after taxes	€ 95,102 Profit after taxes 2022: € 95,102 First fiscal year in the series	€ 10,080 Profit after taxes 2023: € 10,080 ▼ 89% vs 2022 (€ 95,102) Unfavourable step	€ 87,380 Profit after taxes 2024: € 87,380 ▲ € 77,300 vs 2023 (€ 10,080) Favourable step	€ 25,225 Profit after taxes 2025: € 25,225 ▼ 71% vs 2024 (€ 87,380) Unfavourable step	▼ 71%
Equity	€ 134,410 Equity 2022: € 134,410 First fiscal year in the series	€ 144,490 Equity 2023: € 144,490 ▲ 7% vs 2022 (€ 134,410) Favourable step	€ 146,870 Equity 2024: € 146,870 ▲ 2% vs 2023 (€ 144,490) Favourable step	€ 146,896 Equity 2025: € 146,896 Unchanged (€ 146,870) Favourable step
Total debts	€ 373,163 Total debts 2022: € 373,163 First fiscal year in the series	€ 440,026 Total debts 2023: € 440,026 ▲ 18% vs 2022 (€ 373,163) Unfavourable step	€ 386,358 Total debts 2024: € 386,358 ▼ 12% vs 2023 (€ 440,026) Favourable step	€ 278,794 Total debts 2025: € 278,794 ▼ 28% vs 2024 (€ 386,358) Favourable step	▼ 28%
Cash	€ 63,569 Cash 2022: € 63,569 First fiscal year in the series	€ 80,732 Cash 2023: € 80,732 ▲ 27% vs 2022 (€ 63,569) Favourable step	€ 81,072 Cash 2024: € 81,072 Unchanged (€ 80,732) Favourable step	€ 62,294 Cash 2025: € 62,294 ▼ 23% vs 2024 (€ 81,072) Unfavourable step	▼ 23%
Land & buildings	€ 5,016 Land & buildings 2022: € 5,016 First fiscal year in the series	€ 4,477 Land & buildings 2023: € 4,477 ▼ 11% vs 2022 (€ 5,016) Unchanged	€ 5,162 Land & buildings 2024: € 5,162 ▲ 15% vs 2023 (€ 4,477) Unchanged	€ 4,495 Land & buildings 2025: € 4,495 ▼ 13% vs 2024 (€ 5,162) Unchanged	▼ 13%
Retained profit	€ 115,410 Retained profit 2022: € 115,410 First fiscal year in the series	€ 125,490 Retained profit 2023: € 125,490 ▲ 9% vs 2022 (€ 115,410) Favourable step	€ 127,870 Retained profit 2024: € 127,870 ▲ 2% vs 2023 (€ 125,490) Favourable step	€ 127,896 Retained profit 2025: € 127,896 Unchanged (€ 127,870) Favourable step
Dividend	€ 90,000 Dividend 2022: € 90,000 First fiscal year in the series	€ 0 Dividend 2023: € 0 ▼ 100% vs 2022 (€ 90,000) Unchanged	€ 85,000 Dividend 2024: € 85,000 Unchanged (€ 0) Unchanged	€ 25,200 Dividend 2025: € 25,200 ▼ 70% vs 2024 (€ 85,000) Unchanged	▼ 70%
Bank debt	€ 146,636 Bank debt 2022: € 146,636 First fiscal year in the series	€ 126,632 Bank debt 2023: € 126,632 ▼ 14% vs 2022 (€ 146,636) Favourable step	€ 106,628 Bank debt 2024: € 106,628 ▼ 16% vs 2023 (€ 126,632) Favourable step	€ 86,624 Bank debt 2025: € 86,624 ▼ 19% vs 2024 (€ 106,628) Favourable step	▼ 19%
Balance sheet total	€ 507,573 Balance sheet total 2022: € 507,573 First fiscal year in the series	€ 584,517 Balance sheet total 2023: € 584,517 ▲ 15% vs 2022 (€ 507,573) Unchanged	€ 533,228 Balance sheet total 2024: € 533,228 ▼ 9% vs 2023 (€ 584,517) Unchanged	€ 425,689 Balance sheet total 2025: € 425,689 ▼ 20% vs 2024 (€ 533,228) Unchanged	▼ 20%
Employees (FTE)	0 Employees (FTE) 2022: 0 First fiscal year in the series	0 Employees (FTE) 2023: 0 Unchanged (0) Unchanged	0.3 Employees (FTE) 2024: 0.3 Unchanged (0) Unchanged	0.3 Employees (FTE) 2025: 0.3 Unchanged (0.3) Unchanged

Key figures of CORIPHAR, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to CORIPHAR?

What happened at CORIPHAR in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 28, 2026 New annual accounts for financial year 2025: profit of € 25,225 (▼ 71% vs 2024). filed late Source: NBB ↗
2008 Apotheek Tramstatie became a director. NBB
Oct 1, 1990 New establishment in Tienen. KBO
Apr 4, 1989 Start of the company according to the CBE. KBO

In short

From € 95,102 profit in 2022 to € 25,225 profit in 2025.

Paid € 14,608 in corporate taxes since 2022.

Best year ever: 2022, with € 95,102 profit.

Paid out € 200,200 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

APOTHEEK TRAMSTATIE 100%

The stake of APOTHEEK TRAMSTATIE comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

CORIPHAR

Behind CORIPHAR is Apotheek Tramstatie. The shares are held by APOTHEEK TRAMSTATIE (100%).

Directors

According to the 2025 annual accounts

Apotheek Tramstatie

Director · represented by Sofie Lemmens

since 2008

Shareholders

APOTHEEK TRAMSTATIE

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Getestraat 81

3300 Tienen

2.049.649.986

Mulkstraat 186

3300 Tienen

Active since 1 October 1990

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

APOTHEEK TRAMSTATIE same network

€ 73,971 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0437.150.690

VAT number

BE 0437.150.690

Registered office

Getestraat 81, 3300 Tienen

Names & denominations

CORIPHAR

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

4 April 1989

Peppol

Active · Active since 23 Jan 2026

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

View on CBE Public ↗ Annual accounts (NBB) ↗

CORIPHAR

Financials

What happened to CORIPHAR?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions